News | 02 July 2012
Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of cash. Illumina (NASDAQ: ILMN) had $1.27 billion in total cash and $815.97 million in total debt for the latest quarter. Onyx Pharmaceuticals (NASDAQ: ONXX) had ...
Click on the link to read the full article at Benzinga
(This link will open in a new window)